BB-522 Health Sciences
Our lab is engaged in the study of molecular biology and cellular immunology of infectious diseases, with particular interests in drug discovery, pathogenesis and protective antigens for vaccines. Towards drug discovery, we study the protozoan pathogens that cause Chagas' disease (Trypanosoma cruzi), African sleeping sickness (Trypanosoma brucei), leishmaniasis, cryptosporidiosis, toxoplasmosis, and malaria. We use structure-based drug design, targeting protein kinases, to help find new compounds that are active against these protozoan parasites. We use molecular techniques such as genetic deletions (knock outs) and structure-activity correlations to test our hypothesis that these enzymes are good drug targets. We have developed high-throughput techniques for testing the activity of compound sets against molecular targets and against mammalian forms of these parasites in vitro. We also have developed rodent models for testing the activity of these compounds in vivo. Finally, our lab examines hit compounds for in vitro and in vivo pharmacokinetic/ADME and toxicological properties to push the hits to pre-clinical leads.
Copyright © 2003-2013 Molecular & Cellular Biology Program, University of Washington
Fred Hutchison Cancer Research Center | University of Washington
Institute for Systems Biology | Seattle Biomed